نورڤاسك ٥ ملغ 이스라엘 - 아랍어 - Ministry of Health

نورڤاسك ٥ ملغ

pfizer pharmaceuticals israel ltd - amlodipine as besylate 5 mg - tablets - amlodipine - mild to moderate hypertension. vasospastic angina ( prinzmetal's or variant angina). chronic stable angina.

نورڤاسك ١٠ ملغ 이스라엘 - 아랍어 - Ministry of Health

نورڤاسك ١٠ ملغ

pfizer pharmaceuticals israel ltd - amlodipine as besylate 10 mg - tablets - amlodipine - mild to moderate hypertension. vasospastic angina ( prinzmetal's or variant angina). chronic stable angina.

تيرازوسين تيڤع ٥ ملغ 이스라엘 - 아랍어 - Ministry of Health

تيرازوسين تيڤع ٥ ملغ

teva pharmaceutical indust.ltd - terazosin as hydrochloride dihydrate 5 mg - tablets - terazosin - for symptomatic treatment of urinary obstructon caused by benign prostatic hyperplasia (bph). for mild to moderate hypertension.

أليندرونات تيڤع ٧٠ ملغ 이스라엘 - 아랍어 - Ministry of Health

أليندرونات تيڤع ٧٠ ملغ

teva pharmaceutical indust.ltd - alendronic acid as sodium 70 mg - tablets - alendronic acid - for the treatment of osteoporosis in postmenopausal women to prevent fractures, including those of the hip and spine (vertebral compression fractures).treatment to increase bone mass in men with osteoporosis.

روپينيرول تيڤع ٢ ملغ 이스라엘 - 아랍어 - Ministry of Health

روپينيرول تيڤع ٢ ملغ

teva pharmaceutical indust.ltd - ropinirole as hydrochloride 2 mg - film coated tablets - ropinirole - treatment of idiopathic parkinson's disease : ropinirole may be used alone in the treatment of idiopathic parkinson's disease.addition of ropinirole to levodopa may be used to control " on - off " fluctuations and permit a reduction in the total daily dose of levodopa.

سرترالين تيڤع ٥٠ ملغ 이스라엘 - 아랍어 - Ministry of Health

سرترالين تيڤع ٥٠ ملغ

teva pharmaceutical indust.ltd - sertraline as hydrochloride 50 mg - tablets - sertraline - for the treatment of symptoms of depression in patients with or without a history of mania. following satisfactory response, continuation with sertaline therapy is effective in preventing relapse of the initial episode of depression or recurrence of further depressive episodes.

ڤينلافاكسين XR تيڤع ٧٥ ملغ 이스라엘 - 아랍어 - Ministry of Health

ڤينلافاكسين xr تيڤع ٧٥ ملغ

teva pharmaceutical indust.ltd - venlafaxine as hydrochloride 75 mg - capsules - venlafaxine - for the treatment of depression. maintenance of recurrent depression. generalized anxiety disorder (gad) - short term and long-term. social anxiety disorder (sad).

مونتيلوكاست تيڤع ۱٠ ملغ 이스라엘 - 아랍어 - Ministry of Health

مونتيلوكاست تيڤع ۱٠ ملغ

teva pharmaceutical indust.ltd - montelukast as sodium 10 mg - tablets - montelukast - montelukast teva is indicated in adult and adolescents 15 years of age and older for the prophylaxis and chronic treatment of asthma including prevention of daytime and nighttime symptoms the treatment of aspirin-sensitive asthmatic patients and the prevention of exercise-induced bronchoconstriction. montelukast teva is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma. montelukast teva and inhaled corticosteroids may be used concomitantly with additive effects to control asthma or to reduce the inhaled corticosteroid dose while maintaining clinical stability. montelukast teva is indicated for the relief of symptoms of seasonal allergic rhinitis in adults and adolescents 15 years of age and older.

دورزولاميد تيڤع ٢٪ 이스라엘 - 아랍어 - Ministry of Health

دورزولاميد تيڤع ٢٪

teva pharmaceutical indust.ltd - dorzolamide as hydrochloride 2 % - ophthalmic solution - dorzolamide - for the treatment of elevated intracular pressure (iop) in patients with ocular hypertension, open-angle glaucoma and in some patients with secondary glaucoma.

سيبروفلوكساسين تيڤع ٢٥٠ ملغ أقراص 이스라엘 - 아랍어 - Ministry of Health

سيبروفلوكساسين تيڤع ٢٥٠ ملغ أقراص

teva pharmaceutical indust.ltd - ciprofloxacin as hydrochloride 250 mg - tablets - ciprofloxacin - broad spectrum antibiotic for infections caused by ciprofloxacin sensitive pathogens: invasive infections of the external ear. treatment of acute pulmonary exacerbation of cystic fibrosis associated with p. aeruginosa infections in pediatric patients aged 5-17 years.